Takeda announces fda acceptance of nda resubmission of tak-721 (budesonide oral suspension) for the short-term treatment of eosinophilic esophagitis (eoe)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has accepted for review its new drug application (nda) resubmission for tak-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esophagitis (eoe), a chronic inflammatory disease that can cause damage to the esophagus.1 the resubmission is intended to address previous fda feedback to the company's origi.
TAK Ratings Summary
TAK Quant Ranking